These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31945121)

  • 41. Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.
    Miyaji EN; Vadesilho CF; Oliveira ML; Zelanis A; Briles DE; Ho PL
    Clin Vaccine Immunol; 2015 Feb; 22(2):213-20. PubMed ID: 25520146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
    Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae.
    Miyaji EN; Dias WO; Gamberini M; Gebara VC; Schenkman RP; Wild J; Riedl P; Reimann J; Schirmbeck R; Leite LC
    Vaccine; 2001 Dec; 20(5-6):805-12. PubMed ID: 11738744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Immunogenicity and Protection of Two Pneumococcal Protein Vaccines Based on PsaA and PspA.
    Yu J; Li B; Chen X; Lu J; Wang D; Gu T; Kong W; Wu Y
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29610257
    [No Abstract]   [Full Text] [Related]  

  • 46. In-silico design and evaluation of an epitope-based serotype-independent promising vaccine candidate for highly cross-reactive regions of pneumococcal surface protein A.
    Afshari E; Cohan RA; Sotoodehnejadnematalahi F; Mousavi SF
    J Transl Med; 2023 Jan; 21(1):13. PubMed ID: 36627666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
    Watanabe M; Nagai M; Funaishi K; Endoh M
    Vaccine; 2000 Dec; 19(9-10):1199-203. PubMed ID: 11137257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.
    Roberts M; Cropley I; Chatfield S; Dougan G
    Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades.
    Darrieux M; Moreno AT; Ferreira DM; Pimenta FC; de Andrade ALSS; Lopes APY; Leite LCC; Miyaji EN
    J Med Microbiol; 2008 Mar; 57(Pt 3):273-278. PubMed ID: 18287288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
    Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
    J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of antibodies and IL17-mediated immunity in protection against pneumococcal otitis media.
    Habets MN; van Selm S; van Opzeeland FJ; Simonetti E; Hermans PWM; de Jonge MI; Diavatopoulos DA
    Vaccine; 2016 Nov; 34(48):5968-5974. PubMed ID: 27771185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice.
    Ezoe H; Akeda Y; Piao Z; Aoshi T; Koyama S; Tanimoto T; Ishii KJ; Oishi K
    Vaccine; 2011 Feb; 29(9):1754-61. PubMed ID: 21219977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
    Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
    Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.
    Tiru M; Jäätmaa E; Gillenius P; Askelöf P
    Dev Biol Stand; 1985; 61():469-75. PubMed ID: 2872128
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
    Arulanandam BP; Lynch JM; Briles DE; Hollingshead S; Metzger DW
    Infect Immun; 2001 Nov; 69(11):6718-24. PubMed ID: 11598043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
    Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
    Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes.
    Poulain-Godefroy O; Menozzi FD; Alonso S; Vendeville C; Capron A; Locht C; Riveau G
    Scand J Immunol; 2003 Nov; 58(5):503-10. PubMed ID: 14629622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults.
    Tran Minh NN; He Q; Edelman K; Putto-Laurila A; Arvilommi H; Viljanen MK; Mertsola J
    Vaccine; 2000 Apr; 18(19):1971-4. PubMed ID: 10706957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.